source
- Immunovant halts lupus program after Phase 2b trial fails to meet efficacy endpointsImmunovant announced that its anti‑FcRn drug imeroprubart (IMVT‑1402) did not achieve the primary endpoint in a Phase 2b study in patients with cutaneous lupus erythematosus. The double‑blind tria…
- US to End Personal Medication Import Loophole as New Customs Rule Takes EffectA new regulation will begin next month that ends the longstanding loophole allowing Americans to import prescription drugs by mail. The rule, reported by the Wall Street Journal, requires any medic…